Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin

Andrea A Berry, Remon Abu-Elyazeed, Clemente Diaz-Perez, Maurice A Mufson, Christopher J Harrison, Michael Leonardi, Jerry D Twiggs, Christopher Peltier, Stanley Grogg, Antonio Carbayo, Steven Shapiro, Michael Povey, Carmen Baccarini, Bruce L Innis, Ouzama Henry, Andrea A Berry, Remon Abu-Elyazeed, Clemente Diaz-Perez, Maurice A Mufson, Christopher J Harrison, Michael Leonardi, Jerry D Twiggs, Christopher Peltier, Stanley Grogg, Antonio Carbayo, Steven Shapiro, Michael Povey, Carmen Baccarini, Bruce L Innis, Ouzama Henry

Abstract

One combined measles-mumps-rubella (MMR) vaccine without Human Serum Albumin (HSA) is currently licensed in the USA (M-M-R II; Merck, USA) and another has been developed (Priorix™ [MMR-RIT, GSK, Belgium]). In this follow-up study, children from USA or Puerto Rico, who had received one dose of M-M-R II or MMR-RIT at 12-15 months of age in the primary study (NCT00861744), were followed-up for 2 y post-vaccination. Anti-measles and anti-rubella antibodies were measured using Enzyme-Linked Immunosorbent Assay (ELISA), and anti-mumps antibodies using ELISA and plaque reduction neutralization (PRN) assays. Serious adverse events (SAEs) were recorded during the entire follow-up. The according-to-protocol (ATP) persistence cohort included 752 children (M-M-R II = 186, MMR-RIT = 566), who received primary vaccination at a mean age of 12.3 ( ± 0.67) months. 104 children were revaccinated with MMR-containing vaccines; therefore, serology results for timepoints after revaccination were excluded from the analysis. Seropositivity for measles (Year 1≥ 98.3%; Year 2≥ 99.4%) and rubella (Year 1≥ 98.9%; Year 2 = 100%) remained as high at Year 2 as at Day 42. Similarly, seropositivity for mumps determined by ELISA (Year 1≥ 90.1%; Year 2≥ 94.1%) and PRN assays (Year 1≥ 87.5%; Year 2≥ 91.7%) persisted. Thirty-three SAEs were recorded in 23 children; 2 SAEs (inguinal adenitis and idiopathic thrombocytopenic purpura) and one SAE (febrile convulsion) were considered as potentially related to MMR-RIT and M-M-R II, respectively. This study showed that antibodies against measles, mumps and rubella persisted for up to 2 y post-vaccination with either MMR vaccine in children aged 12-15 months, and that both vaccines were well-tolerated during the follow-up period.

Keywords: MMR vaccine; Priorix; antibody persistence; measles; mumps; rubella.

Figures

Figure 1.
Figure 1.
Disposition of participants in the total vaccinated cohort (persistence phase). ATP, according-to-protocol; MMR: Measles Mumps Rubella vaccine. *For children revaccinated at any point in the study, data were censored from analysis for timepoints after revaccination.

References

    1. Banatvala JE, Brown DWG. Rubella. Lancet 2004; 363:1127-37;
    1. Papania MJ, Wallace GS, Rota PA, Icenogle JP, Fiebelkorn AP, Armstrong GL, Reef SE, Redd SB, Abernathy ES, Barskey AE. Elimination of endemic measles, rubella, and congenital rubella syndrome from the Western hemisphere: the US experience. JAMA Pediatr 2014; 168:148-55; PMID:24311021;
    1. McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1-34; PMID:23760231
    1. World Health Organization (WHO) Global measles and rubella strategic plan: 2012–2020. Geneva; 2012. [accessed 2017March01]. .
    1. Centers for Disease Control and Prevention (CDC) Vaccine specific coverage among children 19–35 months, National Immunization Survey, 1994–2014. 2015. Aug 27 [accessed 2016October15]. Available at: .
    1. Zipprich J, Winter K, Hacker J, Xia D, Watt J, Harriman K. Measles outbreak—California, December 2014–February 2015. MMWR Morb Mortal Wkly Rep 2015; 64:153-4; PMID:25695321
    1. Muscat M. Who gets measles in Europe? J Infect Dis 2011; 204:S353-S65;
    1. Clemmons NS, Gastanaduy PA, Fiebelkorn AP, Redd SB, Wallace GS. Measles—United States, January 4–April 2, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:373-6; PMID:25879894
    1. Centers for Disease Control and Prevention (CDC) Measles Cases and Outbreaks. 2017. Feb 09 [accessed 2017March01]. Available at: .
    1. World Health Organization (WHO) Children in typhoon-hit Tacloban, Philippines, receive vaccines against measles, polio [accessed 2016. Feb 18] .
    1. Centers for Disease Control and Prevention (CDC) Measles-Transmission of measles. 2015. [accessed 2016October16]. Available at: .
    1. Mumps: the green book, chapter 23 [accessed 2016October19]. Available at: .
    1. Mufson MA, Diaz C, Leonardi M, Harrison CJ, Grogg S, Carbayo A, Carlo-Torres S, JeanFreau R, Quintero-Del-Rio A, Bautista G, et al.. Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12–15 Months. J Pediatric Infect Dis Soc 2015; 4:339-48; PMID:26582873;
    1. Wellington K, Goa KL. Measles, Mumps, Rubella Vaccine (Priorix™ GSK-MMR). Drugs 2003; 63:2107-26; PMID:12962524;
    1. Rojo CC, Iglesias MRg, Olvera J, Girón MÁ. Study of the immune response engendered by differents combined measles, mumps and rubella (MMR) vaccines in an area of Andalusia (Spain). Vaccine 2003; 22:280-6;
    1. Committee for medicinal products for human use Guideline on the investigation of manufacturing processes for plasma-derived medicinal products with regard to vcjd risk. 2004. Oct [accessed 2016October16] .
    1. Wiedmann RT, Reisinger KS, Hartzel J, Malacaman E, Senders SD, Giacoletti KE, Shaw E, Kuter BJ, Schodel F, Musey LK. M-M-R((R))II manufactured using recombinant human albumin (rHA) and M-M-R((R))II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children. Vaccine 2015; 33:2132-40; PMID:25796337;
    1. Crovari P, Gabutti G, Giammanco Gt, Dentico P, Moiraghi A, Ponzio F, Soncini R, for the Study TCG . Reactogenicity and immunogenicity of a new combined measles–mumps–rubella vaccine: results of a multicentre trial. Vaccine 2000; 18:2796-803; PMID:10812221;
    1. Stuck B, Stehr K, Bock H. Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age. Asian Pac J Allergy Immunol 2002; 20:113-20; PMID:12403196
    1. Usonis V, Bakasenas V, Kaufhold A, Chitour K, Clemens R. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children. Pediatr Infect Dis J 1999; 18:42-8; PMID:9951979;
    1. Dine MS, Hutchins SS, Thomas A, Williams I, Bellini WJ, Redd SC. Persistence of vaccine-induced antibody to measles 26–33 years after vaccination. J Infect Dis 2004; 189(Suppl 1):S123-30; PMID:15106101;
    1. Harmsen T, Jongerius M, Van Der Zwan C, Plantinga A, Kraaijeveld C, Berbers G. Comparison of a neutralization enzyme immunoassay and an enzyme-linked immunosorbent assay for evaluation of immune status of children vaccinated for mumps. J Clin Microbiol 1992; 30:2139-44; PMID:1500523
    1. Usonis V, Bakasenas V, Denis M. Neutralization activity and persistence of antibodies induced in response to vaccination with a novel mumps strain, RIT 4385. Infection 2001; 29:159-62; PMID:11440387;
    1. Centers for Disease Control and Prevention (CDC) Yellow Book, Chapter 3. Infectious diseases related to travel. 2015. Sep 10 [accessed 2016October25]. Available at: .
    1. Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Evid Based Child Health 2013; 8:2076-238.
    1. Latner D, Hickman C, Condit RC. Remembering Mumps. PLoS Pathog 2015; 11:e1004791; PMID:25951183;
    1. Pipkin P, Afzal M, Heath A, Minor P. Assay of humoral immunity to mumps virus. J Virol Methods 1999; 79:219-25; PMID:10381091;

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever